Chemotherapy-Induced Epidermal Growth Factor Receptor Activation Determines Response to Combined Gefitinib/Chemotherapy Treatment in Non-Small Cell Lung Cancer Cells

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-05-0446
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Epidermal Growth Factor Receptor Activity Determines Response of Colorectal Cancer Cells to Gefitinib Alone and in Combination With Chemotherapy

Clinical Cancer Research
Cancer ResearchOncology
2005English

Combining Chemotherapy With Epidermal Growth Factor Receptor Inhibition in Advanced Non-Small Cell Lung Cancer

Therapeutic Advances in Medical Oncology
Oncology
2012English

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors vs Conventional Chemotherapy in Non–Small Cell Lung Cancer Harboring Wild-Type Epidermal Growth Factor Receptor

JAMA - Journal of the American Medical Association
Medicine
2014English

Morphine-Induced Epidermal Growth Factor Pathway Activation in Non–Small Cell Lung Cancer

Anesthesia and Analgesia
AnesthesiologyPain Medicine
2011English

Can Intercalating Chemotherapy With Epidermal Growth Factor Receptor Inhibitors Delay Development of Treatment Resistance in Advanced Non-Small Cell Lung Cancer?

Expert Opinion on Pharmacotherapy
MedicinePharmacology
2017English

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non-Small-Cell Lung Cancer to Gefitinib

Yearbook of Pulmonary Disease
2006English

Epidermal Growth Factor Receptor Status and Notch Inhibition in Non-Small Cell Lung Cancer Cells

Journal of Biomedical Science
Cell BiologyPharmacologyBiochemistryEndocrinologyClinical BiochemistryMolecular BiologyMedicineMetabolismDiabetes
2015English

Enhancement of Epidermal Growth Factor Receptor-Degradation Pathway in Acquired Gefitinib-Resistant Human Non-Small Cell Lung Cancer Cell Lines

The Showa University Journal of Medical Sciences
2004English

OA14 Phase 2 Study: Tepotinib + Gefitinib in MET+/Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy